Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
The 2018 "Dr. Ragnar Mørk's legacy prize" goes to Kaisa Haglund, head of the "Cytokinesis in development and carcinogenesis project group" at the Department of Molecular Cell Biology, for her outstanding research on cell division and cancer.. This award of NOK 200.000 is annually given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research. The ceremony will take place on Friday November 23rd in seminar rooms 1+2 om the Research Building at Montebello, starting at 14:30. Kaisa Haglund will then give a lecture about the research activities that has earned her the award.
The prestigious journal Nature Methods recently published an article by proteomics researchers at the Department of Immunology. "We describe a simple and affordable method for large-scale protein analysis and test the specificity of 6000 commercially available antibodies to human proteins" says Fridtjof Lund-Johansen, who led the study. The findings are drawing attention, and the major national news outlet for health and medicine "Dagens Medisin" has covered the story.
Proteins are the building blocks of cells and tissues, and they operate in complex clockworks to exert a host of biological functions. The purpose of large-scale protein analysis, or proteomics, is to dissect these clockworks and understand how they operate. Most drugs act by modifying the function of one or more proteins, so there is good reason to believe that insight from proteomics research will open new avenues for therapy.
The latest issue of Molecular Oncology features an ImmunoFISH image from the article “Intratumor heterogeneity defines treatment resistant HER2+ breast tumors”, as their cover image.
In the article published in the same issue Inga H. Rye, post doc in the Russnes group, combined immunofluorescence and in situ hybridization (ImmunoFISH) on tissue sections and analyzed more than 13 000 single tumor cells from 37 HER2+ breast tumors. By a validated computational approach previously developed by the group (GoIFISH, Trinh et al. Genome Biology 2016), they found a subset of HER2+ breast carcinomas to exhibit substantial heterogeneity with regard to HER2 protein expression, HER2 gene copy number alteration, and estrogen receptor protein expression.
The vast majority of primary prostate cancers are multifocal. The individual tumors within the prostate gland are known to have different aggressiveness and develop independently of one another, but little has been known about their genetic relationship.
Marthe Løvf and colleagues have performed the first large in-depth genomic heterogeneity study of primary prostate cancer and the results were published in the recognized journal European Urology earlier this month. The researchers performed exome sequencing of 89 tumor foci from 41 patients and demonstrated convincingly that the different foci within the same patient only exceptionally have any somatic gene mutations in common.
From major journals, first or last author from the Institute for Cancer Research
Herrera MC, Chymkowitch P, Robertson JM, Eriksson J, Bøe SO, Alseth I, Enserink JM(2018) Cdk1 gates cell cycle-dependent tRNA synthesis by regulating RNA polymerase III activity Nucleic Acids Res(in press) DOI 10.1093/nar/gky1102, PubMed 30395271
Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V(2018) Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab Oncoimmunology, 7(11), e1457598 DOI 10.1080/2162402X.2018.1457598, PubMed 30377556
Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ(2018) Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells Semin Immunopathol(in press) DOI 10.1007/s00281-018-0721-x, PubMed 30361801